Epidemiology of idiosyncratic drug-induced liver injury

Lauren N. Bell, Naga Chalasani

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Idiosyncratic drug-induced liver injury (DILI) is a significant health problem because of its unpredictable nature, poorly understood pathogenesis, and potential to cause fatal outcomes. It is also a significant hurdle for drug development and marketing of safe prescription medications. Idiosyncratic DILI is generally rare, but its occurrence is likely underappreciated due to the lack of active reporting or surveillance systems and substantial challenges involved in its recognition and diagnosis. Nonetheless, DILI is a common cause of potentially serious and fatal acute liver failure in both children and adults. Population-based studies that accurately estimate the incidence and full spectrum of DILI are limited. However, using a prospective, population-based French study with an annual estimated incidence of 13.92.4 DILI cases per 100,000 inhabitants, it has been extrapolated that nearly 44,000 individuals in the United States will suffer from DILI each year. Although increasing numbers of patients are also being seen with DILI due to herbal and dietary supplements, the epidemiology of this entity requires further investigation. In this article, the epidemiology of DILI, both in the general population and in potentially high-risk subgroups, is reviewed.

Original languageEnglish
Pages (from-to)337-347
Number of pages11
JournalSeminars in Liver Disease
Volume29
Issue number4
DOIs
StatePublished - 2009

Fingerprint

Chemical and Drug Induced Liver Injury
Epidemiology
Population
Fatal Outcome
Acute Liver Failure
Incidence
Dietary Supplements
Marketing
Prescriptions
Health

Keywords

  • Acute liver failure
  • Adverse drug reaction
  • Hepatotoxicity
  • Idiosyncratic

ASJC Scopus subject areas

  • Hepatology

Cite this

Epidemiology of idiosyncratic drug-induced liver injury. / Bell, Lauren N.; Chalasani, Naga.

In: Seminars in Liver Disease, Vol. 29, No. 4, 2009, p. 337-347.

Research output: Contribution to journalArticle

@article{5342fbeaf3734e0bb5ab1f8d48a6b1e1,
title = "Epidemiology of idiosyncratic drug-induced liver injury",
abstract = "Idiosyncratic drug-induced liver injury (DILI) is a significant health problem because of its unpredictable nature, poorly understood pathogenesis, and potential to cause fatal outcomes. It is also a significant hurdle for drug development and marketing of safe prescription medications. Idiosyncratic DILI is generally rare, but its occurrence is likely underappreciated due to the lack of active reporting or surveillance systems and substantial challenges involved in its recognition and diagnosis. Nonetheless, DILI is a common cause of potentially serious and fatal acute liver failure in both children and adults. Population-based studies that accurately estimate the incidence and full spectrum of DILI are limited. However, using a prospective, population-based French study with an annual estimated incidence of 13.92.4 DILI cases per 100,000 inhabitants, it has been extrapolated that nearly 44,000 individuals in the United States will suffer from DILI each year. Although increasing numbers of patients are also being seen with DILI due to herbal and dietary supplements, the epidemiology of this entity requires further investigation. In this article, the epidemiology of DILI, both in the general population and in potentially high-risk subgroups, is reviewed.",
keywords = "Acute liver failure, Adverse drug reaction, Hepatotoxicity, Idiosyncratic",
author = "Bell, {Lauren N.} and Naga Chalasani",
year = "2009",
doi = "10.1055/s-0029-1240002",
language = "English",
volume = "29",
pages = "337--347",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Epidemiology of idiosyncratic drug-induced liver injury

AU - Bell, Lauren N.

AU - Chalasani, Naga

PY - 2009

Y1 - 2009

N2 - Idiosyncratic drug-induced liver injury (DILI) is a significant health problem because of its unpredictable nature, poorly understood pathogenesis, and potential to cause fatal outcomes. It is also a significant hurdle for drug development and marketing of safe prescription medications. Idiosyncratic DILI is generally rare, but its occurrence is likely underappreciated due to the lack of active reporting or surveillance systems and substantial challenges involved in its recognition and diagnosis. Nonetheless, DILI is a common cause of potentially serious and fatal acute liver failure in both children and adults. Population-based studies that accurately estimate the incidence and full spectrum of DILI are limited. However, using a prospective, population-based French study with an annual estimated incidence of 13.92.4 DILI cases per 100,000 inhabitants, it has been extrapolated that nearly 44,000 individuals in the United States will suffer from DILI each year. Although increasing numbers of patients are also being seen with DILI due to herbal and dietary supplements, the epidemiology of this entity requires further investigation. In this article, the epidemiology of DILI, both in the general population and in potentially high-risk subgroups, is reviewed.

AB - Idiosyncratic drug-induced liver injury (DILI) is a significant health problem because of its unpredictable nature, poorly understood pathogenesis, and potential to cause fatal outcomes. It is also a significant hurdle for drug development and marketing of safe prescription medications. Idiosyncratic DILI is generally rare, but its occurrence is likely underappreciated due to the lack of active reporting or surveillance systems and substantial challenges involved in its recognition and diagnosis. Nonetheless, DILI is a common cause of potentially serious and fatal acute liver failure in both children and adults. Population-based studies that accurately estimate the incidence and full spectrum of DILI are limited. However, using a prospective, population-based French study with an annual estimated incidence of 13.92.4 DILI cases per 100,000 inhabitants, it has been extrapolated that nearly 44,000 individuals in the United States will suffer from DILI each year. Although increasing numbers of patients are also being seen with DILI due to herbal and dietary supplements, the epidemiology of this entity requires further investigation. In this article, the epidemiology of DILI, both in the general population and in potentially high-risk subgroups, is reviewed.

KW - Acute liver failure

KW - Adverse drug reaction

KW - Hepatotoxicity

KW - Idiosyncratic

UR - http://www.scopus.com/inward/record.url?scp=70449113012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449113012&partnerID=8YFLogxK

U2 - 10.1055/s-0029-1240002

DO - 10.1055/s-0029-1240002

M3 - Article

VL - 29

SP - 337

EP - 347

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 4

ER -